Pfizer: Oncology Research and Development Presentation Highlights Next-Generation Blockbusters
We are holding firm to our fair value for Pfizer following the firm’s oncology research and development presentation that showed a strong lineup of new potential blockbusters. The wide breadth of Pfizer’s cancer drug pipeline reinforces our undervalued view of the stock, as the market appears to underappreciate the company’s pipeline. The strong pipeline also reinforces Pfizer’s wide moat rating.